Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $160.49 | 10 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $48.53 | 2 | $0 (2024) |
| Collegium Pharmaceutical, Inc. | $46.86 | 3 | $0 (2020) |
| Allergan, Inc. | $14.39 | 1 | $0 (2020) |
| Horizon Therapeutics plc | $13.77 | 1 | $0 (2020) |
| ABBVIE INC. | $13.07 | 1 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $12.07 | 1 | $0 (2020) |
| Arbor Pharmaceuticals, Inc. | $11.80 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48.53 | 2 | Otsuka America Pharmaceutical, Inc. ($48.53) |
| 2022 | $13.07 | 1 | ABBVIE INC. ($13.07) |
| 2020 | $98.89 | 7 | Collegium Pharmaceutical, Inc. ($46.86) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/05/2024 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $26.10 | General |
| Category: NEUROLOGY | ||||||
| 01/31/2024 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: NEUROLOGY | ||||||
| 08/30/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: NEUROSCIENCE | ||||||
| 12/22/2020 | Arbor Pharmaceuticals, Inc. | Horizant (Drug) | Food and Beverage | In-kind items and services | $11.80 | General |
| Category: Sleep | ||||||
| 12/08/2020 | Horizon Therapeutics plc | PENNSAID (Drug) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: PENNSAID | ||||||
| 12/01/2020 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: HYPERHYDROSIS | ||||||
| 11/17/2020 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $14.69 | General |
| Category: Opioid Analgesic | ||||||
| 07/28/2020 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $20.65 | General |
| Category: Opioid Analgesic | ||||||
| 03/10/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $12.07 | General |
| Category: Central Nervous System | ||||||
| 02/18/2020 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $11.52 | General |
| Category: Opioid Analgesic | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,011 | 9,872 | $2.9M | $800,570 |
| 2022 | 8 | 1,068 | 8,557 | $2.2M | $597,203 |
| 2021 | 8 | 644 | 2,051 | $418,843 | $142,553 |
| 2020 | 10 | 1,648 | 2,500 | $401,831 | $219,384 |
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 258 | 4,795 | $1.5M | $440,436 | 28.4% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 251 | 3,796 | $926,224 | $240,341 | 25.9% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 232 | 415 | $198,785 | $53,335 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 60 | 449 | $134,750 | $39,211 | 29.1% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 67 | 67 | $39,262 | $10,296 | 26.2% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Facility | 2023 | 57 | 139 | $21,823 | $4,349 | 19.9% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 13 | 37 | $7,178 | $3,330 | 46.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 50 | $11,000 | $3,233 | 29.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $6,650 | $2,717 | 40.9% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 17 | 17 | $7,786 | $1,942 | 24.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 13 | $7,605 | $1,316 | 17.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 11 | 75 | $1,600 | $63.30 | 4.0% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 316 | 4,491 | $960,449 | $258,023 | 26.9% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 292 | 3,211 | $922,083 | $248,822 | 27.0% |
| 99305 | Initial nursing facility visit per day, typically 35 minutes | Facility | 2022 | 203 | 401 | $163,094 | $43,847 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 42 | 224 | $67,200 | $19,616 | 29.2% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Facility | 2022 | 141 | 146 | $74,246 | $19,272 | 26.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 26 | 26 | $9,100 | $3,773 | 41.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 35 | 45 | $10,692 | $2,725 | 25.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 13 | $4,860 | $1,125 | 23.2% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 128 | 1,445 | $273,105 | $86,382 | 31.6% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Facility | 2021 | 99 | 104 | $47,424 | $14,900 | 31.4% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 56 | 56 | $16,800 | $11,129 | 66.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 116 | 138 | $22,770 | $10,095 | 44.3% |
| 99305 | Initial nursing facility visit, typically 35 minutes per day | Facility | 2021 | 45 | 60 | $21,660 | $6,697 | 30.9% |
About Dr. Kamara Savage, M.D
Dr. Kamara Savage, M.D is a Physical Medicine & Rehabilitation healthcare provider based in Long Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/20/2012. The National Provider Identifier (NPI) number assigned to this provider is 1780941203.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kamara Savage, M.D has received a total of $160.49 in payments from pharmaceutical and medical device companies, with $48.53 received in 2024. These payments were reported across 10 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($160.49).
As a Medicare-enrolled provider, Savage has provided services to 4,371 Medicare beneficiaries, totaling 22,980 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Practice Information
- Specialty Physical Medicine & Rehabilitation
- Location Long Beach, CA
- Active Since 04/20/2012
- Last Updated 07/13/2022
- Taxonomy Code 208100000X
- Entity Type Individual
- NPI Number 1780941203
Products in Payments
- NUEDEXTA (Drug) $48.53
- XTAMPZA (Drug) $46.86
- BOTOX (Biological) $14.39
- PENNSAID (Drug) $13.77
- UBRELVY (Drug) $13.07
- AJOVY (Biological) $12.07
- Horizant (Drug) $11.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physical Medicine & Rehabilitation Doctors in Long Beach
Dr. Jason Koh, D.o, D.O
Physical Medicine & Rehabilitation — Payments: $4,125
Kimberly Bedell, M.d, M.D
Physical Medicine & Rehabilitation — Payments: $3,902
Nathaniel Dusto, Md, MD
Physical Medicine & Rehabilitation — Payments: $1,987
Dr. Edward Barawid, D.o, D.O
Physical Medicine & Rehabilitation — Payments: $1,739
Dr. Ronald Takemoto, M.d, M.D
Physical Medicine & Rehabilitation — Payments: $1,457
Diemha Hoang, M.d, M.D
Physical Medicine & Rehabilitation — Payments: $1,336